208182-75-6

Usage

Physical state

Yellow solid at room temperature

Usage

Commonly used in organic synthesis and pharmaceutical research

Odor

Mild aromatic

Role

Key intermediate in the production of various pharmaceuticals, agrochemicals, and fine chemicals

Application

Used as a reagent in the synthesis of biologically active compounds

Field of interest

Potential applications in the field of medicinal chemistry

Potential properties

Studied for its potential anti-inflammatory and analgesic properties

Upstream product

• 108-89-4 picoline 
• 207681-67-2 N-methoxy-N-methyl-3-bromobenzamide 
• 618-89-3 methyl 3-bromobenzoate 
• 24398-88-7 ethyl 3-bromobenzoate 

Downstream Products

• 208182-76-7 1-(3-bromophenyl)-2-pyridin-4-ylethane-1,2-dione 
• 1206835-51-9 4-[3-(3-bromophenyl)-1H-pyrazol-4-yl]pyridine 
• 1314258-64-4 3-[1-phenyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]benzoic acid 
• 1314264-05-5 1-phenyl-3-(3-bromophenyl)-4-(pyridin-4-yl)-1H-pyrazole 
• 1206835-50-8 (2E)-1-(3-bromophenyl)-3-(dimethylamino)-2-pyridin-4-ylprop-2-en-1-one 
• 208182-72-3 4-[5-(3-bromo-phenyl)-2-(4-chloro-phenyl)-3H-imidazol-4-yl]-pyridine 

Relevant academic research and scientific papers

RAF KINASE INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS

3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS

3,4-diaryl-bicyclicpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invent

Substituted imidazoles as glucagon receptor antagonists

A modestly active, nonselective triarylimidazole lead was optimized for binding affinity with the human glucagon receptor. This led to the identification of a 2- and/or 4-alkyl or alkyloxy substituent on the imidazole C4-aryl group as a structural determinant for significant enhancement in binding with the glucagon receptor (e.g., 41, IC50 = 0.053 μM) and selectivity (> 1000 ×) over p38 MAP kinase in this class of compounds.